Targeting HDAC6 to Modulate Titin Stiffness for Dilated Cardiomyopathy Therapy
Targeting HDAC6 to Modulate Titin Stiffness for Dilated Cardiomyopathy Therapy
批准号:
10080922
负责人:
Frederick Albert Schroeder
金额:
$30.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-01 至 2022-08-31
关键词:
AccountingAdrenergic AgentsAdultAdverse effectsAffectAmericanAngiotensin IIAngiotensin ReceptorBiopsyBiotechnologyBrainCardiac MyocytesCardiomyopathiesCardiovascular DiseasesCause of DeathCell surfaceCessation of lifeCharacteristicsChemicalsChronicCollaborationsCountryCytoplasmic ProteinDataDeacetylaseDevelopmentDilated CardiomyopathyDiseaseDoseDrug TargetingEFRACEchocardiographyElementsEnzymesFunctional disorderGenesGeneticHDAC6 geneHealthHealth ExpendituresHealthcare SystemsHeartHeart DiseasesHeart TransplantationHeart failureHospitalizationHumanImpairmentIndividualInvestmentsKnock-outKnowledgeLeadLeftMalignant NeoplasmsMassachusettsMeasurementMedical ResearchMessenger RNAMissionModelingMolecularMorbidity - disease rateMusMutationMyocardial dysfunctionMyofibrilsNational Heart, Lung, and Blood InstituteNerve DegenerationNeurodegenerative DisordersOxygenPatientsPeripheral Nervous System DiseasesPharmaceutical ChemistryPharmaceutical PreparationsPopulationPositron-Emission TomographyPrevalenceProtein Binding DomainProteinsPublic HealthPumpRNA BindingRNA SplicingRattusResearchSeriesSignal TransductionSocietiesSyndromeTestingTherapeuticUnited StatesUnited States National Institutes of HealthVascular blood supplyVentricularVentricular DysfunctionWorkalpha Tubulinbaseclinical developmentconnectincostdesigndisabilitydrug candidatedrug discoveryearly onsetefficacy testingfamilial dilated cardiomyopathygenetic approachheart functionhemodynamicsimaging agentimprovedin vivoinhibitor/antagonistinnovationlead optimizationmortalitymouse modelnovelpostnatal developmentpreservationprogramsresearch clinical testingsmall molecule inhibitorstandard of care
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Dilated cardiomyopathy (DCM) is associated with impaired systolic/pump function of the heart, which can lead
to heart failure and death. It is estimated that 1 in 250 adults in the U.S. have DCM, with ~40% of these cases
being attributed to genetic causes. A common characteristic of DCM is reduced stiffness of titin. Titin is a
molecular spring that provides passive tension to the heart by functioning within contractile units known as
myofibrils. It is believed that re-establishing titin spring function (i.e. stiffening titin) in DCM patients could provide
an innovative, disease-modifying approach to treat cardiomyopathy. Unpublished findings from our collaborator,
Dr. McKinsey, reveal a remarkable ability of the cytoplasmic protein, histone deacetylase 6 (HDAC6), to control
the stiffness of titin. The long-term objective of the proposed work is to develop an HDAC6-selective small
molecule inhibitor as a ‘titin stiffener’ to improve systolic function and treat DCM in humans. This is in-line with
the mission of the NHLBI, which includes treatment of heart disease to enhance the health of individuals so they
can live longer and more fulfilling lives. One specific aim is to rank-order novel HDAC6 inhibitors (discovered by
Eikonizo Therapeutics) for their ability to increase titin stiffness in cultured adult rat cardiomyocytes, and for their
ability to improve systolic cardiac function in a short-term mouse model of heart failure. In a second specific aim,
compounds that advance through these initial filters will be tested for efficacy in a rat model of DCM characterized
by severe titin softening. This rat model recapitulates many elements of RBM20 (RNA-binding motif protein 20,
a splicing factor that targets titin) cardiomyopathy, an aggressive and early onset genetic DCM in humans. This
drug discovery proposal has the potential to facilitate the development of transformative therapies to treat DCM
in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金